Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study

Area of Science:

• Pharmacokinetics and Drug Bioavailability
• Pharmaceutical Sciences
• Clinical Pharmacology

Background:

• The
• Drug substitution, particularly generic-generic, requires rigorous bioavailability assessment to ensure therapeutic equivalence.
• Understanding potential
• drift
• in drug product performance over time is crucial for patient safety.

Purpose of the Study:

• To evaluate the comparative bioavailability of three generic gabapentin formulations against a branded reference product.
• To investigate the phenomenon of
• drift
• in generic-generic drug substitution of gabapentin.
• To assess the interchangeability of different gabapentin formulations.

Main Methods:

• A single-dose, four-way crossover comparative bioavailability study.
• Involved 24 healthy subjects receiving 800 mg gabapentin formulations.
• Analyzed key pharmacokinetic parameters including AUC(0-t) and C(max) with 90% confidence intervals.

Main Results:

• All three generic gabapentin formulations demonstrated bioequivalence to the branded product.
• Ninety percent confidence intervals for AUC(0-t) and C(max) fell within the 80-125% acceptance range for all comparisons.
• Comparable safety profiles were observed across all tested gabapentin formulations.

Conclusions:

• The generic gabapentin formulations are bioequivalent to the branded product and to each other.
• The study indicates the absence of
• drift
• with generic-generic substitution of gabapentin.
• These findings support the interchangeability of the evaluated gabapentin formulations.